報價延遲最少15分鐘:2024/11/16 09:01 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.64 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.48/-0.13
|
|
企業價值
86.90M
|
| 資產負債 |
|
每股賬面淨值
-0.32
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
70.19M
|
|
每股收益
2.03
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/11/16 09:01 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensingof the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe. |